Show Summary Details
Page of

Dendritic Cell Vaccine Therapy for Ovarian Cancer 

Dendritic Cell Vaccine Therapy for Ovarian Cancer
Dendritic Cell Vaccine Therapy for Ovarian Cancer

Caitlin Stashwick

, Brian J. Czerniecki

, and Janos L. Tanyi

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 11 July 2020

Dendritic cell vaccine therapy has emerged as an exciting new field in immunotherapy in ovarian cancer over the past two decades. This chapter reviews the biology of dendritic cells, including dendritic cell subsets, development, activation, and maturation as well as strategies for clinical use of dendritic cell vaccines. While there is encouraging data in preclinical work for dendritic cell vaccine, the outcomes of clinical trials have not shown robust responses. A summary of the clinical trials using dendritic cell vaccines in ovarian cancer is reviewed. Treatment-related toxicities and potential therapies to increase clinical efficacy are also discussed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.